{"id":"docetaxel-pm","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Constipation"},{"rate":"5-15%","effect":"Mucositis"},{"rate":"5-15%","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Docetaxel-PM binds to tubulin and promotes the assembly of microtubules, leading to the stabilization of microtubules and the inhibition of cell division. This results in the induction of apoptosis in rapidly dividing cancer cells.","oneSentence":"Docetaxel-PM is a taxane chemotherapy medication that works by inhibiting microtubule dynamics, thereby inducing apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:34:03.315Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT07007988","phase":"PHASE1","title":"A Phase I Study of SIM0388 in Participants With Malignant Ascites.","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2025-04-24","conditions":"Malignant Ascites","enrollment":50},{"nctId":"NCT05800587","phase":"PHASE2","title":"Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2023-02-22","conditions":"Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT05254665","phase":"PHASE2","title":"A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2022-02","conditions":"Advanced Solid Tumors","enrollment":110},{"nctId":"NCT04066335","phase":"","title":"Study to Evaluate the Safety of Nanoxel M Inj.","status":"UNKNOWN","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2019-09-18","conditions":"Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer","enrollment":1498},{"nctId":"NCT01951157","phase":"PHASE2","title":"A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients","status":"COMPLETED","sponsor":"PharmaMar","startDate":"2013-09-11","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":69},{"nctId":"NCT02982395","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC","status":"TERMINATED","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2017-01","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":36},{"nctId":"NCT01685983","phase":"PHASE2","title":"A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-08-30","conditions":"Prostate Cancer","enrollment":82},{"nctId":"NCT03585673","phase":"PHASE2","title":"Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma","status":"UNKNOWN","sponsor":"Sung Yong Oh","startDate":"2018-06-01","conditions":"Esophagus Squamous Cell Carcinoma (SCC), Metastatic Cancer","enrollment":38},{"nctId":"NCT02639858","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC","status":"UNKNOWN","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2015-10","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":31},{"nctId":"NCT01336582","phase":"PHASE1","title":"Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer","status":"COMPLETED","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2009-08","conditions":"Solid Tumor","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NANOXEL-M","Nanoxel M"],"phase":"phase_2","status":"active","brandName":"Docetaxel-PM","genericName":"Docetaxel-PM","companyName":"Sung Yong Oh","companyId":"sung-yong-oh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel-PM is a taxane chemotherapy medication that works by inhibiting microtubule dynamics, thereby inducing apoptosis in cancer cells. Used for Non-small cell lung cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}